US-based biomaterial company Amedica has introduced its new Valeo II anterior lumbar (AL) interbody fusion device, indicated for intervertebral body fusion of the spine in skeletally mature patients.
The silicon nitride anterior lumbar interbody fusion device is designed for use with autograft to facilitate fusion.
The Valeo II AL interbody fusion device is made of Silicon Nitride biomaterial which has anti-infective properties with superior bone growth, along with proven anti-infective properties.
The redesigned device is semi-radiolucent with clearly visible boundaries in x-rays and will not produce artifacts under magnetic resonance imaging or computed tomography.
Amedica president and CEO Eric K Olson noted the company is committed to delivering products that address the changing needs of spinal surgeons.
"Our next generation Silicon Nitride AL device provides an optimal environment for bone growth while reducing the risk for infection due to its innate anti-infective properties. These benefits have the potential to improve the efficacy of spinal fusion procedures resulting in enhanced patient care.
"As Amedica continues to collaborate with surgeons to develop innovative, safe and effective interbody fusion devices, Silicon Nitride is increasingly becoming the gold standard material for spinal fusion devices," Olson added.
"With the launch of Valeo II AL, Amedica is positioned to rapidly increase our market share in the $1.6B interbody fusion device market."
When compared to competitive offerings, the Valeo II AL provides a new design that offers improved bone-to-implant interface and resistance to push out, the company reported.
